|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
|
CA2945320A1
(en)
|
2014-04-10 |
2015-10-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Drug regulated transgene expression
|
|
AU2015259877B2
(en)
|
2014-05-15 |
2021-02-25 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
SI3194434T1
(sl)
|
2014-09-15 |
2019-11-29 |
Molmed Spa |
Himerni antigenski receptorji
|
|
JP2017531430A
(ja)
*
|
2014-10-07 |
2017-10-26 |
セレクティスＣｅｌｌｅｃｔｉｓ |
Ｃａｒによって誘導される免疫細胞の活性を調節するための方法
|
|
CN107109438B
(zh)
*
|
2014-11-05 |
2021-09-03 |
朱诺治疗学股份有限公司 |
用于转导及细胞处理的方法
|
|
KR102376244B1
(ko)
|
2014-12-24 |
2022-03-21 |
오토러스 리미티드 |
세포
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
WO2016170541A1
(en)
|
2015-04-21 |
2016-10-27 |
Enlivex Therapeutics Ltd. |
Therapeutic pooled blood apoptotic cell preparations and uses thereof
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
CN107530424A
(zh)
|
2015-02-20 |
2018-01-02 |
俄亥俄州国家创新基金会 |
针对nkg2d和肿瘤相关抗原的二价抗体
|
|
JP2018510627A
(ja)
*
|
2015-03-10 |
2018-04-19 |
レイデン ユニバーシティ メディカル センター |
メラノーマ優先発現抗原に対して向けられたｔ細胞レセプターおよびその使用
|
|
AU2016246457B2
(en)
*
|
2015-04-06 |
2020-10-15 |
Cytoimmune Therapeutics, Inc. |
EGFR-directed car therapy for glioblastoma
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
SG11201708516YA
(en)
|
2015-04-17 |
2017-11-29 |
David Maxwell Barrett |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
WO2016166887A1
(ja)
*
|
2015-04-17 |
2016-10-20 |
三菱電機株式会社 |
表示制御装置、表示システム、表示制御方法および表示制御プログラム
|
|
EP3322801A1
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
AU2016297014B2
(en)
*
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
WO2017027291A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
|
CA2999037A1
(en)
*
|
2015-09-23 |
2017-03-30 |
Cytoimmune Therapeutics, LLC |
Flt3 directed car cells for immunotherapy
|
|
EA201891338A1
(ru)
|
2015-12-04 |
2018-12-28 |
Новартис Аг |
Композиции и способы для иммуноонкологии
|
|
AU2017207936A1
(en)
*
|
2016-01-15 |
2018-07-26 |
Etubics Corporation |
Methods and compositions for T-cell immunotherapy
|
|
EP3408297A2
(en)
|
2016-01-29 |
2018-12-05 |
Med Manor Organics, (P) Ltd |
A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
|
|
CN109069539A
(zh)
|
2016-02-18 |
2018-12-21 |
恩立夫克治疗有限责任公司 |
用于癌症治疗的联合免疫疗法和细胞因子控制疗法
|
|
CN109069537B
(zh)
*
|
2016-04-04 |
2022-04-15 |
亘喜生物科技（上海）有限公司 |
共刺激结构域中具有重复结合基序的car
|
|
US20190328783A1
(en)
*
|
2016-04-15 |
2019-10-31 |
Cellectis |
A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression
|
|
US10894093B2
(en)
|
2016-04-15 |
2021-01-19 |
Cellectis |
Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
US11851491B2
(en)
*
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
CN110352068A
(zh)
|
2016-12-02 |
2019-10-18 |
南加利福尼亚大学 |
合成的免疫受体及其使用方法
|
|
EP3581190B1
(en)
|
2016-12-09 |
2021-03-10 |
ONK Therapeutics Limited |
Engineered natural killer cells and uses thereof
|
|
CN110291200B
(zh)
|
2016-12-12 |
2024-05-14 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
|
|
WO2018175636A2
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
KR102660336B1
(ko)
|
2017-03-27 |
2024-04-26 |
내셔널 유니버시티 오브 싱가포르 |
절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
|
|
MX2019011570A
(es)
|
2017-03-27 |
2019-11-18 |
Nat Univ Singapore |
Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
|
|
CN107164412B
(zh)
*
|
2017-06-30 |
2020-10-23 |
山东兴瑞生物科技有限公司 |
一种安全型抗cea嵌合抗原受体修饰t细胞的制备方法及其应用
|
|
IL316570A
(en)
*
|
2017-12-05 |
2024-12-01 |
Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct |
T cells containing chimeric receptors for CD138 and CD38 antigens and their use
|
|
EP3720882A4
(en)
*
|
2017-12-05 |
2021-10-27 |
The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center |
T-CELLS WITH TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND THEIR USE
|
|
AU2019219454A1
(en)
|
2018-02-09 |
2020-08-27 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
CN112055717B
(zh)
|
2018-04-02 |
2024-04-26 |
新加坡国立大学 |
用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
US12590148B2
(en)
|
2018-11-26 |
2026-03-31 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
EP3917967A4
(en)
*
|
2019-02-01 |
2023-02-08 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Microenvironment sensors to regulate engineered gene expression
|
|
GB201902277D0
(en)
*
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
CN113924103B
(zh)
*
|
2019-03-06 |
2025-02-14 |
莱蒂恩技术公司 |
用于用自驱动的嵌合抗原受体来治疗癌症的组合物和方法
|
|
WO2020181983A1
(zh)
*
|
2019-03-12 |
2020-09-17 |
重庆精准生物技术有限公司 |
缺氧调控启动子及其应用
|
|
CN111686128A
(zh)
*
|
2019-03-12 |
2020-09-22 |
重庆精准生物技术有限公司 |
一种缺氧可调控的启动子在car-t中的应用
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
CA3160759A1
(en)
*
|
2019-12-05 |
2021-06-10 |
Vycellix, Inc. |
Modulators of the immune escape mechanism for universal cell therapy
|
|
EP4221726A4
(en)
*
|
2020-09-30 |
2024-10-30 |
Baylor College of Medicine |
CYTOTOXIC AND CO-STIMULATORY CHIMERIC ANTIGEN RECEPTORS
|
|
EP4334361A1
(en)
|
2021-05-05 |
2024-03-13 |
Immatics Biotechnologies GmbH |
Antigen binding proteins specifically binding prame
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
NL2037929B1
(en)
|
2024-06-11 |
2026-01-12 |
Prinses Maxima Centrum Voor Kinderoncologie B V |
Brain Organoid
|